جستجوی استاد راهنمای دانشگاهی

Hutan Ashrafianمشاهده پروفایل

استاد

• Artificial Intelligence in Medicine
• Metabolic Surgery
• Health Policy
• +۴ مورد دیگر

Professor Hutan Ashrafian is a clinician-scientist and surgeon at the University of Leeds Business School, holding dual roles as Professor of Research Impact and Senior Research Fellow at Imperial College London. His expertise spans AI in healthcare, metabolic surgery, and ancient history. He pioneered STARD-AI and QUADAS-AI guidelines for AI diagnostics, collaborated on AI-driven breast cancer screening with Google and NHS, and led global health policy initiatives. Ashrafian’s work bridges medicine, history, and philosophy, including his contributions to understanding historical figures’ medical conditions, such as King Tutankhamun’s epilepsy. He has authored over 550 publications, 12 books, and holds a PhD in computational physiology and an MBA with distinction. Awards include the Hunterian Prize and Wellcome Trust Fellowship. His research also explores AI ethics, quantum physics paradoxes, and art-based medical diagnostics. Education: PhD in Computational Physiology (Imperial College London) MBA (Warwick Business School) MD (University College London) Bachelor of Science in Immunology (University College London) Research Interests: Ashrafian’s work spans: AI in Medicine: Diagnostic algorithms, guideline development (STARD-AI/QUADAS-AI), and ethical frameworks. Metabolic Surgery: Bariatric interventions, gut microbiome, and obesity treatments. Ancient History: Medical analyses of historical figures (e.g., Tutankhamun, Julius Caesar) and art-based pathology identification. Philosophy: AI rights (AIONAI law), temporal paradoxes, and the Simulation Argument. Awards: Royal College of Surgeons Arris and Gale Lectureship Hunterian Prize Wellcome Trust Research Fellowship Advising & Innovation: Supervised >50 PhD students, co-founded Oxford Medical Products (weight loss tech), and serves as CSO at Flagship Pioneering’s Preemptive Health division. He advises on NHS digital transformation and global health policy. Labs/Teams: Leads AI initiatives at Imperial’s Institute of Global Health Innovation and collaborates with Google, NICE, and international institutions on health tech solutions.

Jimeng Sunمشاهده پروفایل

استاد

• Artificial Intelligence
• Healthcare Analytics
• Drug Discovery
• +۵ مورد دیگر

Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .

• Gynecologic Oncology
• Ovarian Cancer
• Breast Cancer
• +۵ مورد دیگر

Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it

Youngjae Youمشاهده پروفایل

استاد

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +۳ مورد دیگر

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

Martin T. Wellsمشاهده پروفایل

استاد

• Applied Statistics
• Theoretical Statistics
• Bayesian Statistics
• +۷ مورد دیگر

Martin T. Wells is the Charles A. Alexander Professor of Statistical Sciences at Cornell University, with joint appointments in the Department of Statistical Science, Department of Biological Statistics and Computational Biology, Department of Social Statistics, and as Professor of Clinical Epidemiology and Health Services Research at Weill Medical School. He serves as Editor-in-Chief of the ASA-SIAM Book Series and Co-Editor of the Journal of Empirical Legal Studies. Cornell University, Ithaca, NY Weill Cornell Medical College Research Interests span applied and theoretical statistics, Bayesian methods, biostatistics, clinical epidemiology, and computational biology. His work bridges disciplines like finance, legal studies, and health services research. Article Trends highlight advancements in Bayesian modeling, quantum cognition machine learning, tensor analysis, and misclassification correction, with applications in genomics, finance, and public health. Fellow of the American Statistical Association Fellow of the Royal Statistical Society Contributions include developing statistical software (e.g., rTensor), methodological innovations in clinical trials, and empirical legal studies on civil rights and the death penalty.

Joel Gohمشاهده پروفایل

دانشیار

• Health services and systems
• Transportation, logistics and supply chains
• Operations research
• +۶ مورد دیگر

Joel Goh is Associate Professor at the Department of Analytics and Operations, NUS Business School, National University of Singapore. He serves as Director of the J.Y. Pillay Comparative Asia Research Centre (under NUS Global Asia Institute) and PhD Program Director at the Institute of Operations Research and Analytics (IORA). Previously, he was Assistant Professor at Harvard Business School (2014-2017) and Visiting Scholar (2017-2022). BSc, MSc, PhD in Operations, Information, and Technology from Stanford University His research focuses on healthcare analytics (preventing health conditions, hospital operations, frailty assessment), supply chain analytics (digital business models, platform leakage), and service platform operations (hospital-at-home programs, incentive design). He co-created the Robust Optimization Made Easy (ROME) software. Recent publications analyze workplace psychological safety (2024), hospital-at-home models (2024), and platform leakage dynamics (2023). His work spans 18+ journals with 740+ citations for burnout cost studies (2022) and 606+ citations for physician well-being research (2017). Teaching Honors : 2023: Best MBA Teaching & Skinner Innovation Award 2021: NUS Annual Teaching Excellence Award 2020: Early Career Research Excellence Award & 40 Under 40 Best MBA Professors Advising & Grants : Served as PhD Program Director. Received NUS Start-Up Grant R-314-000-110-133 (2021) and Humanities & Social Sciences Fellowship (2021). Editorial roles include Associate Editor at Management Science , Manufacturing & Service Operations Management , and Senior Editor at Production and Operations Management .

Andre Levchenkoمشاهده پروفایل

استاد

• Systems Biology
• Signal Transduction
• Cell Communication
• +۵ مورد دیگر

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Michael McAlpineمشاهده پروفایل

استاد

• 3D Printing
• Nanotechnology
• Biomedical Engineering
• +۴ مورد دیگر

Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award

Wengong Jinمشاهده پروفایل

استادیار

• AI for drug discovery
• Generative AI models
• Geometric deep learning
• +۵ مورد دیگر

Wengong Jin is an Assistant Professor at the Khoury College of Computer Sciences, Northeastern University, and a visiting research scientist at the Eric and Wendy Schmidt Center at the Broad Institute. He holds a PhD from MIT CSAIL, advised by Prof. Regina Barzilay and Prof. Tommi Jaakkola. Research Interests: His work focuses on geometric and generative AI models for drug discovery, biology, and chemical engineering. Key areas include equivariant neural networks (e.g., FAFormer), diffusion models for binding energy prediction, antibody/enzyme design (RefineGNN, SurfPro), and molecular design through graph neural networks (Junction Tree VAE). He also explores domain generalization and systems for autonomous molecular discovery. Publications: His research has been published in top venues like NeurIPS, ICLR, ICML, Nature, Science, and Cell. Recent breakthroughs include discovering novel antibiotics using explainable AI and designing synergistic drug combinations for cancer treatment. Awards: He has received the BroadIgnite Award, Dimitris N. Chorafas Prize, and MIT EECS Outstanding Thesis Award for his contributions to computational biology and AI-driven drug discovery. Teaching: Currently teaches a PhD seminar on AI for Science, focusing on integrating machine learning into scientific discovery processes.

Min Huمشاهده پروفایل

استادیار

• Health Economics
• Applied Microeconomics
• Labour Economics
• +۷ مورد دیگر

Min Hu is an Assistant Professor in the Department of Economics, Philosophy, and Political Science at the University of British Columbia, Okanagan Campus. He holds an adjunct position at Dalhousie University's School of Health Administration. His primary research focuses on Health Economics, Applied Microeconomics, and Labour Economics, with an emphasis on vulnerable populations in Canada, Indigenous health, income inequalities, and cancer economics. He teaches courses in Microeconomics, Health Economics, and Statistics. Education: PhD in Economics (2019), Dalhousie University; Postdoctoral Fellowship in Health Economics (2019–2020), Dalhousie University. Previous degrees include an M.A. (2014–2016) and B.A. in Economics from Dalhousie University. Research interests include the socio-economic determinants of health disparities, particularly among Indigenous peoples and immigrants, and the economic impacts of cancer-related policies. He employs applied econometric methods to analyze labor market outcomes and social policy effectiveness. His recent articles explore sustainable biomass utilization, energy policies, and environmental engineering innovations. Key themes include biomass supply chain optimization, CO₂ reduction strategies, and waste-to-energy technologies. Scientific Awards: Recipient of SSHRC New Frontiers Grant (2023–2026), CIHR Team Grant (2024–2026), and multiple UBC startup grants. His work is supported by SSHRC, CRDCN, and Indigenous Services Canada. He advises students in Economics and Global Studies (IGS) programs. Grants and funding span health economics, Indigenous well-being, and sustainable energy systems. Collaborations include interdisciplinary teams in health administration and environmental policy. Labs/Teams: Engaged with UBC's Okanagan Sustainability Initiatives and Dalhousie's Health Economics Research Group. Affiliated with professional organizations like the American Economic Association and Canadian Health Economics Study Group.

Paul Stuppleمشاهده پروفایل

استاد

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

Illya V. Hicksمشاهده پروفایل

استاد

• Combinatorial Optimization
• Integer Programming
• Graph Theory
• +۵ مورد دیگر

Illya V. Hicks is a Professor in the Computational and Applied Mathematics Department at Rice University. He holds a PhD from Rice University (2000) and a BS from Texas State University (1995). His research focuses on combinatorial optimization, integer programming, graph theory, and matroid theory, with applications in social networks, cancer treatment, and network design. He has advised numerous doctoral, post-doctoral, and masters students. Education: PhD and MA in Computational and Applied Mathematics, Rice University, 2000 BS in Mathematics, Texas State University, 1995 Research Interests: Utilizing graph decomposition techniques to solve NP-complete problems, including branch decompositions and matroid circuit problems. Applications include sensor network design, healthcare logistics, and algorithmic graph theory. Awards: Recognized with the 2015 Presidential Mentoring Award (Rice University), 2010 Forum Moving Spirit Award (INFORMS), and the 2005 Optimization Prize for Young Researchers. Grants and Projects: Includes NSF-funded research on branch decomposition techniques, submodular optimization, and healthcare service distribution. Active in promoting minority participation in operations research through travel grants and mentoring initiatives. Labs/Teams: Engaged in collaborative research on graph algorithms, combinatorial optimization, and interdisciplinary applications in healthcare and engineering.

• Statistical Reinforcement Learning
• Mobile Health (mHealth)
• Clinical Trials
• +۳ مورد دیگر

Susan A. Murphy is the Mallinckrodt Professor of Statistics and of Computer Science at Harvard University, with affiliations to the Kempner Institute. She leads the Statistical Reinforcement Learning Lab, focusing on developing algorithms to inform sequential decision-making in health, particularly for Just-in-Time Adaptive Interventions (JITAIs) and micro-randomized trials (MRTs). Her work is funded by NIH institutes, including NIDA, NHLBI, and NIBIB. Dr. Murphy has been awarded a MacArthur Fellowship (2013) and is a member of the National Academy of Medicine (2014) and the National Academy of Sciences (2016). Her research integrates statistical methods with computer science techniques to optimize mobile health interventions. She collaborates with d3Lab and mDOT on projects like HeartSteps and Sense2Stop, evaluating real-time treatment policies. Notable contributions include advancing MRT designs, sample size calculations, and reinforcement learning algorithms for personalized healthcare. Dr. Murphy advises a large team of postdocs, graduate students, and undergraduates, many of whom hold academic and industry roles globally. She emphasizes engagement in digital interventions, balancing personalization with ethical considerations. Her lab’s work spans algorithm development, clinical trial design, and causal inference, aiming to improve health outcomes through adaptive interventions.

Ahmet Acarمشاهده پروفایل

دانشیار

• Cancer Biology
• Precision Medicine
• Drug Resistance Mechanisms
• +۳ مورد دیگر

Dr. Ahmet Acar is an Associate Professor at the Department of Biological Sciences, Middle East Technical University (METU), Ankara, Turkey. He leads the Cancer Precision Medicine and Drug Resistance Laboratory, focusing on understanding mechanisms of drug resistance in cancer. His research integrates experimental models, next-generation sequencing, and deep learning to address clinical challenges in cancer therapy. Dr. Acar holds a B.Sc. from METU's Biological Sciences department and a Ph.D. from the Cancer Research UK Manchester Institute. He completed postdoctoral training at the Institute of Cancer Research, London, and the University of Manchester. Research Interests: Drug resistance mechanisms, precision oncology, tumor microenvironment modeling, patient-derived organoids, computational pathology, and evolutionary cancer biology. His lab develops 2D/3D co-culture systems, PDO biobanks, and AI-driven histopathology tools to improve treatment strategies. Recent Work Trends: Recent publications emphasize tumor evolution modeling, matrix mechanics in drug resistance, and AI applications in histopathology. Collaborations with hospitals in Turkey and Europe support PDO biobank initiatives. His team explores evolutionary steering strategies to exploit collateral drug sensitivities. Labs/Teams: Precision Medicine and Drug Resistance Lab at METU focuses on interdisciplinary approaches combining wet-lab experiments with computational methods. Current projects include ex vivo tumor modeling and AI-driven diagnostic tools for oncology.